Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
No Thumbnail Available
Identifiers
Date
2021-01-01
Authors
del Carmen Alamo, Ma
Ochenduszko, Sebastian
Crespo, Guillermo
Corral, Monica
Oramas, Juana
Sancho, Pilar
Medina, Javier
Garicano, Fernando
Lopez, Pedro
Campos Balea, Begona
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Dove medical press ltd
Metrics
Export
Abstract
Background: The combination of BRAF and MEK inhibitors delays the onset of resistance and provides more sustained and dramatic responses in comparison with a BRAF inhibitor in monotherapy. The objective of the study was to evaluate the effectiveness of the combination therapy with vemurafenib/cobimetinib in terms of durability, and to describe differential characteristics in patients associated to durable responses in real-world settings.Patients and Methods: Retrospective, observational, cross-sectional, multicenter study involving 41 patients with advanced melanoma harboring a BRAF(v600) mutation who initiated a combination therapy with vemurafenib/cobimetinib between May 2018 and March 2019. Participants were differentiated regarding the durability of the response: durable (complete response, CR, or a partial response, PR, for at least 12 months) and non-durable (stable disease, SD, progressive disease, PD, or CR/PR
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
vemurafenib, cobimetinib, BRAF, metastatic melanoma, durable response, clinical practice, Combination, Mortality, Outcomes, Therapy, Cohort, V600e